Embecta Corp.
HealthcareNASDAQ:EMBC · NASDAQ Global Select
+$0.02 today
Vol 1.54M · Avg 1.92M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-14.7%
avg 22.9%
ROIC
27.4%
avg 44.6%
ROA
8.7%
avg 30.0%
Analysis
ROIC is currently the strongest return metric at 27.4% versus its period average of 44.6%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Devdatt Kurdikar | President, CEO & Chairman | $2.40M | — | 57 | $903,548.73 | 1.52% |
Shaun Curtis | Senior Vice President of Global Manufacturing & Supply Chain | $1.17M | — | 56 | $95,323.55 | 0.16% |
Jacob Elguicze | Senior Vice President & Chief Financial Officer | $1.16M | — | 53 | $0.00 | <0.01% |
Jeffrey Z. Mann | Senior Vice President, General Counsel, Head of Business Development & Corporate Secretary | $1.11M | — | 54 | $0.00 | <0.01% |
Jean Casner | Senior Vice President & Chief Human Resources Officer | $854,983.00 | — | 68 | $88,029.65 | 0.15% |
Anthony Roth | Vice President, Chief Accounting Officer & Corporate Controller | $645,161.00 | — | 53 | $78,833.15 | 0.13% |
Pravesh Khandelwal | Vice President & Head of Investor Relations | — | — | — | — | — |
Slobodan Radumilo | Senior Vice President & President of International | — | — | 55 | — | — |
Tom Blount | Senior Vice President & President of North America | — | — | 52 | — | — |
Ginny Blocki | Senior Vice President of Strategy | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -45.4% | +14.0% (7yr)1 analysts |
| Revenue | N/A | N/A | +1.1% | -0.3% (7yr)2 analysts |
| Net Income | N/A | N/A | -45.2% | +14.4% (7yr)2 analysts |
| EBIT | N/A | N/A | -22.2% | +2.5% (7yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +1.1% over three years. Forward estimates point to Net Income at +14.4% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
CareDx, Inc
NASDAQ:CDNA
$1.19B
Personalis, Inc.
NASDAQ:PSNL
$851.63M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Evolent Health, Inc.
NYSE:EVH
$539.91M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
Emergent BioSolutions Inc.
NYSE:EBS
$429.28M
Aquestive Therapeutics, Inc.
NASDAQ:AQST
$414.11M
Myriad Genetics, Inc.
NASDAQ:MYGN
$408.96M
SIGA Technologies, Inc.
NASDAQ:SIGA
$309.85M
Who manages EMBC?
Embecta Corp. (EMBC) lists 10 active executives. The top listed executive is Devdatt Kurdikar, President, CEO & Chairman.
Are EMBC insiders buying or selling?
Recent insider activity shows net buying of $30.40M.
Explore More
Continue the stock analysis
Jump to another research area for this company.